The Chinese regime has said its controversial virology institute had no relationship with the military, but the institute worked with military leaders on a government-sponsored project for almost a decade.
The Wuhan Institute of Virology (WIV) participated in a project, sponsored by the National Natural Science Foundation of China (NSFC)—a regime-funded scientific research institution—from 2012 to 2018. The project was comprised of a team of five military and civil experts, who conducted research at WIV labs, military labs, and other civil labs leading to “the discovery of animal pathogens [biological agents that causes disease] in wild animals.”
The WIV is located in central China’s Wuhan City, the COVID-19 pandemic ground zero. As an advanced virology institution, the WIV has the only P4 lab—the highest biosafety level lab—in China and the biggest repository of bat coronaviruses in Asia. The CCP (Chinese Communist Party) virus, commonly known as novel coronavirus, is “96 percent identical at the whole-genome level to a bat coronavirus,” Chinese researchers wrote in a research article (pdf) published in February 2020.
In recent months, the Chinese Foreign Affairs Ministry and Shi Zhengli, the WIV virologist nicknamed “Bat Woman” for her research on coronaviruses of bat origin, denied there is a connection between the WIV and military, and said that no WIV researchers were infected with COVID-19.
However, according to an investigation conducted by the U.S. State Department, “several researchers inside the WIV became sick in autumn 2019, before the first identified case of the outbreak, with symptoms consistent with both COVID-19 and common seasonal illnesses.”
“The WIV has engaged in classified research, including laboratory animal experiments, on behalf of the Chinese military since at least 2017,” states a State Department fact sheet.
However, Shi denied that the WIV engaged in research with the Chinese military. “I don’t know of any military work at the WIV. That information is incorrect,” Shi said at a public webinar on March 23. Shi didn’t mention that the WIV was used by a Chinese military medical team in early 2020 for developing COVID-19 vaccines.
Shi told Science magazine in July 2020 that no pathogen leaks or personnel infections had occurred. The magazine reported that according to Shi, “there is ‘zero infection’ among staff or students with SARS-CoV-2 [2019 novel coronavirus] or SARS-related viruses.”
In late March, overseas Chinese media reported that three WIV staff members started to have symptoms similar to COVID-19 as early as November 2019. Soon thereafter, Chinese state-run media China News reported that the news was based on rumors.
China News reported that a Chinese specialist told the WHO investigation team—which visited China in February to investigate the origin of the CCP virus—that cases dating back to 2019 were patients at WIV-related hospitals, rather than members of WIV staff.
The NSFC put research results about the animal pathogens on its website on Feb. 1, 2018. It also stated that the project “discovered over 1,640 types of new viruses by using the metagenomics technology,” and the research was performed by a civil and military team.
Cao Wuchun, 58, a member of the project’s military team, is a colonel and top epidemiologist in the Chinese military. He has been a researcher at the Academy of Military Medical Sciences since September 2017, but has worked there for the last 21 years. He served as the academy’s director from 2007 to 2017, according to his official resume. Cao served on the team as second in command to Major General Chen Wei, China’s top biowarfare expert.
On Jan. 26, 2020, Cao accompanied Chen to Wuhan and they took over command of the WIV. Chinese state-run media reported, at that time, that the main purpose of the military take-over was to develop a vaccine against the CCP virus.
Cao also co-led the NSFC project with Shi (the WIV virologist), and the Chen-Cao team had taken over the WIV when the COVID-19 pandemic broke out in Wuhan.
The other three team leaders of the NSFC project were Liang Guodong, Zhang Yongzhen, and Xu Jianguo, researchers from the Chinese Center for Disease Control and Prevention (CDC). Among them, Xu was the project leader or the manager of the other four team members.
Xu, 69, is the director of the CDC’s state key laboratory for communicable disease prevention and control, a scholar at the Chinese Academy of Engineering, and director of the Research Institute of Public Health at Nankai University. Xu’s resume states that he received $987,820 in funding from the NSFC for the project.
As one of China’s top virus specialists, Xu went to Wuhan to serve as a team leader in early 2020. On Jan. 14, 2020, Xu told China’s Science magazine, “All 763 close contacts aren’t infected. The pandemic isn’t severe, and it might stop next week if there’s no more new infection.”
In fact, Wuhan people started to crowd inside hospitals for their pneumonia symptoms from early January 2020, but the regime refused to recognize that the virus can transmit among humans until Jan. 20, 2020. The late announcements fooled people into traveling and allowed the virus to spread all around the world from Wuhan.
Shi, 56, directs the Center for Emerging Infectious Diseases at WIV. In 2000, she received her Ph. D. degree in virology from the University of Montpellier II in France, after studying there for four years.
Shi started to investigate coronaviruses when China suffered from the severe acute respiratory syndrome (SARS) outbreak in 2002 and 2003.
Beijing authorities said the SARS virus was transmitted from civets (a meat-eating animal) to humans in southern China’s Guangdong Province in November 2002, and spread to other Chinese cities and neighboring Hong Kong because the regime didn’t allow people to discuss this infectious disease in the first two months. SARS eventually killed at least 774 people, and infected 8,096 people from 31 countries.
Chinese state-run CCTV reported on Dec. 29, 2017, that Shi and her team didn’t believe that civets were the natural hosts of SARS, and were only the intermediate host. They started to investigate bats from different Chinese regions in 2004.
In 2011, Shi’s team detected a SARS-like virus from bats living in a cave in southwestern China’s Yunnan Province. They then named this virus “WIV1” and conducted further studies. CCTV didn’t report the details of the virus, but said Shi’s team continued to get samples from the same cave for five years.
Since 2015, Shi’s team has been publishing their test results in international magazines, including Virologica Sinica, Nature, and Lancet.
Weeks after the Chinese regime publicly announced the COVID-19 outbreak, Shi and her team published an article in Nature, linking COVID-19 to bats.
Shi’s team discovered the bat coronavirus in the bats that they had collected from an abandoned copper mine in Tongguan township, Mojiang county in Yunnan Province. The WIV researchers had visited the mine for several days even after six workers had gotten infected while working there.
On July 15, 2020, virologist Jonathan Latham and molecular biologist Allison Wilson from Ithaca, N.Y., co-published an article in Independent Science News after translating a 66-page master’s thesis by Li Xu, a Chinese medical doctor who treated the miners and sent their tissue samples to the WIV for testing.
Li’s thesis was submitted in May 2013. He wrote that six miners removed the bat feces from a mine in April 2012. After working there for 14 days, all workers felt sick with severe symptoms, such as high fever, dry cough, and sore limbs.
Kunming Medical University, School of Clinical Medicine, where Li studied, received and treated the miners. Finally, three of the miners died. Their samples were sent to WIV for further investigation.
UK’s Johnson Urges Talks As Unions Threaten “Biggest Rail Strike In Modern History”
UK’s Johnson Urges Talks As Unions Threaten "Biggest Rail Strike In Modern History"
Authored by Alexander Zhang via The Epoch Times,
British Prime Minister Boris Johnson has urged rail unions to talk to the government before causing “irreparable damage” with strike action.
The National Union of Rail, Maritime, and Transport Workers (RMT) is holding a ballot of its 40,000 members on plans to strike over jobs, pay, and conditions. The ballot is set to close on Tuesday, and the union has claimed that a yes vote could lead to “the biggest rail strike in modern history.”
Another union, the Transport Salaried Staffs’ Association (TSSA), has also warned of a “summer of discontent” with similar action on the way unless pay disputes are resolved.
The prime minister’s official spokesman said on Monday:
“Railways are going through difficult times with passenger numbers down. We need to make sure they’re fit for the future.”
He said the government wants “a fair deal for staff, for passengers, and taxpayers” so that “money isn’t taken away from other essential services” such as the National Health Service.
“The prime minister is firmly of the view that unions should talk to the government before causing irreparable damage to our railways—strikes should be the last resort not the first,” he added.
Transport Secretary Grant Shapps told The Sunday Telegraph that ministers are looking at drawing up laws which would make industrial action illegal unless a certain number of staff are working.
Shapps said the government hopes the unions will “wake up and smell the coffee” and suggested that strikes could put more people off rail travel.
He also accused unions of going straight to industrial action rather than using it as a last resort, adding that railways were already on “financial life support” because of the CCP (Chinese Communist Party) virus pandemic.
Referring to a pledge in the Conservative Party’s 2019 election manifesto, which promised minimum services during rail strikes, he said:
“We had a pledge in there about minimum service levels. If they really got to that point then minimum service levels would be a way to work towards protecting those freight routes and those sorts of things.”
Unions have reacted to the threat with anger.
RMT General Secretary Mick Lynch said, “Any attempt by Grant Shapps to make effective strike action illegal on the railways will be met with the fiercest resistance from RMT and the wider trade union movement.”
He said the government needs to “focus all their efforts on finding a just settlement” to the rail dispute rather than “attack the democratic rights of working people.”
CytoDyn Inc (OTCMKTS: CYDY) On the Comeback Trail (HIV Leronlimab Update)
CytoDyn Inc (OTCMKTS: CYDY) continues to move steadily higher in recent trading since hitting lows of $0.231 after the FDA placed a partial clinical hold…
CytoDyn Inc (OTCMKTS: CYDY) continues to move steadily higher in recent trading since hitting lows of $0.231 after the FDA placed a partial clinical hold on the Company’s HIV program and a full clinical hold on its COVID-19 program in the United States. CYDY was one of the biggest runners of 2020 skyrocketing from pennies to $10 per share and MIcrocapdaily covered the stock regularly back in those exciting times. Since than CYDY has been downward bound, first suffering from the Citron short attack and more recently the March 30 drop after the FDA hold. Further, CytoDyn elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission. CYDY saw further declines after the Company’s CEO and registered public accounting firm, Warren Averett LLC, both resigned.
On May 23 CYDY reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell. The Company will release to Dr. Pestell 8.3 million shares of CYDY held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company’s common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize Leronlimab’s full potential in oncology. This is an important step forward for CytoDyn as any potential suitor would want the current management to clear the deck of lawsuits before initiating a buyout or partnership. Also, an all-stock settlement shows a lot of faith in the Company from Dr. Pestell who make come back. At this point Cytodyn must find a sponsor or partner to get Leronmilab back on track for HIV.
The underlying science of Leronmilab has not changed; leronlimab has demonstrated significant potential to attack a number of diseases including cancer, and HIV. Considering how fast CYDY dropped the bounce potential here is significant and when CYDY does make a definitive move northbound the stock could make rapid gains in a very shorty time period. Management remains hopeful the FDA will review the case and stop the hold of Leronlimab.
Sign Up now for our 100% FREE Penny Stock Newsletter
CytoDyn Inc (OTCMKTS: CYDY) is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.
In January Cytodyn reported positive results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The trial was conducted in two parts. Part 1 compared a 700 mg weekly dose and placebo in a double-blind randomized manner and Part 2 evaluated a 350 mg weekly dose as an open label study compared to the same placebo blinded arm. Results of the topline report will be announced when available.
The pre-clinical and clinical development of PRO 140 was led by Progenics Pharmaceuticals, Inc. through 2011. The Company acquired the asset from Progenics in October 2012. In February 2018, CYDY announced it had met the primary endpoint in its Phase 3 trial for leronlimab as a combination therapy with HAART for highly treatment-experienced HIV patients and first submitted the non-clinical portion of the Company’s Biologics License Application (“BLA”) to the FDA in March 2019.
— TL (@THL99999) May 21, 2022
To Find out the inside Scoop on CYDY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Cytodyns current business strategy is to resubmit its BLA to the FDA as soon as possible, to finalize with the FDA our submitted protocol for a pivotal Phase 3 clinical trial with leronlimab as a monotherapy for HIV patients, to seek emergency use authorization and approval for leronlimab as a potential therapeutic benefit for COVID-19 patients with mild-to-moderate, severe-to-critical, and long-haulers indications in the U.S., Brazil, and other countries, to advance the Company’s clinical trials with leronlimab for various forms of cancer, including, among others, the Phase 2 clinical trial for metastatic triple-negative breast cancer and Phase 2 basket trial for 22 solid tumor cancers, to complete the Phase 2 trial for liver fibrosis associated with nonalcoholic steatohepatitis (“NASH”), and to explore other cancer and immunologic indications for leronlimab.
On May 23 CYDY announced it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company.
Under the terms of the agreement, the parties will release each other of all claims, and the Company will release to Dr. Pestell 8.3 million shares of the Company’s common stock held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company’s common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab’s full potential in oncology. CytoDyn regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell.
Dr. Pestell has published more than 600 works, is the most frequently cited scientist in the field of cell-cycle control and was appointed an Officer of the Order of Australia in the 2019 Queen’s Birthday Honours for distinguished service to medicine and medical education. He has served on editorial boards of six journals, was the Director of two NCI-designated Cancer Centers and has founded several biotechnology companies. He serves as an advisor and reviewer for a number of domestic and international research centers, including NCI cancer centers.
$CYDY 8-K CytoDyn (23 May, 4:03pm)
— Docoh Feed (@investor_feed) May 23, 2022
For More on CYDY Subscribe Right Now!
Currently trading at a $226 million market valuation CYDY is an SEC filer and is fully reporting OTCQB. The Company has close to $100 million in assets and about that in debt. At current price levels CYDY is worth a close look; CYDY was one of the biggest runners of 2020 skyrocketing from pennies to $10 per share. While there are plenty of ricks not to mention the CEO and accounting firm resigning CYDY is moving northbound now and looks to be coming back. The underlying science has not changed; Leronlimab has demonstrated significant potential to attack a number of diseases including cancer and HIV. Considering how fast CYDY dropped the bounce potential here is significant and when CYDY does make a definitive move northbound the stock could make rapid gains in a very shorty time period. Management remains hopeful the FDA will review the case and stop the hold of Leronlimab. We will be updating on CYDY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYDY.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CYDY either long or short and we have not been compensated for this article.
The post CytoDyn Inc (OTCMKTS: CYDY) On the Comeback Trail (HIV Leronlimab Update) first appeared on Micro Cap Daily.emergency use authorization covid-19 treatment fda clinical trials therapy brazil
Immigration Disappears From Kamala Harris’ Public Schedule
Immigration Disappears From Kamala Harris’ Public Schedule
Authored by Philip Wegmann via RealClear Politics (emphasis ours),
It was her…
Authored by Philip Wegmann via RealClear Politics (emphasis ours),
It was her first overseas trip, and Vice President Harris, recently deputized to address what the White House calls “the root causes of migration,” was in Guatemala trying to break through with a simple message. “Do not come,” Harris told would-be migrants last June. “Do not come. The United States will continue to enforce our laws and secure our borders.”
They did not listen, or if any migrants did hear Harris last year, many ignored her message. Just last month, according to U.S. Customs and Border Patrol, 234,088 migrants were apprehended at the southern border, the highest mark ever recorded.
Asked that same month if President Biden had confidence in Harris and her ability to handle the situation, then-White House Press Secretary Jen Psaki replied, “he absolutely does.” But as the flow of migrants accelerates across the southern border, immigration has disappeared from the vice president’s public schedule.
A compilation of that schedule by the Los Angeles Times, reviewed by RealClearPolitics, shows that Harris has not hosted an immigration-specific event since last summer. The last one, a meeting with Asian American, Native Hawaiian, and Pacific Islander leaders in the White House last August, touched briefly on immigration.
White House officials dispute any characterization that Harris’ public schedule tells the whole story. “The vice president continues to lead implementation of the Root Causes Strategy and has been engaging with Cabinet and other Administration officials on this effort,” Harris’ Press Secretary Kirsten Allen told RCP.
Addressing the challenge remains part of the vice president’s policy portfolio. She leads top-level meetings that are not always made public, and she has taken point in diplomatic efforts in the region. For instance, it was Harris who traveled to Honduras for the inauguration of President Xiomara Castro in January. Administration officials hoped to find a new ally in that executive, someone who would help stem the flow of the millions of people heading north through Central America to the southern border. According to an official White House readout, Harris and Castro discussed “a broad range of issues.” Among them migration, but also coronavirus and the economy as well as corruption and gender-based violence.
Despite those efforts, the influx has not slowed, and Biden is expected to end enforcement of Title 42, the pandemic policy that allowed Border Patrol to turn away hundreds of thousands of migrants on public health grounds. Warnings from some Democrats in border states, including Texas Rep. Henry Cuellar, have gone unheeded.
The Department of Homeland Security is bracing for more record-breaking numbers at the border, and NBC News reports that there is concern in the department that they won’t have enough funding to address a surge if Title 42 is lifted, compounding a challenge that Biden has faced since the beginning of his presidency.
As the number of interdictions started to rise and chaotic images from the southern border flooded cable news, concern grew, even among Democrats. Biden’s own pollsters, the New York Times reported, warned that the issue was “a growing vulnerability." Biden still insisted that he could get the situation under control, albeit with divine intervention.
“Is there a crisis at the border?” RCP asked the president as he walked out of the East Room of the White House after a speech last March.
“No,” Biden replied over his shoulder. “We’ll be able to handle it,” he said while walking side-by-side with Harris. “God willing.”
Two weeks later, the Associated Press reported at the time, Biden tapped Harris to lead the administration efforts to tackle the migration challenge at the southern border and work with Central American nations to address root causes of the problem. Republicans were eager to assign blame and dubbed Harris “border czar.”
The vice president rejected that framing and sought to clarify her mission. As the White House press secretary explained to reporters last March, Harris “will be helping lead that effort, specifically the root causes – not the border,” admitting that there has been “some confusion over that.”
The president was also confused: When Biden and Harris met with the Congressional Black Caucus in April that year, he praised his vice president, saying she would do “a hell of a job” handling immigration, according to a new book by New York Times’ reporters Jonathan Martin and Alexander Burns. But Harris corrected him then and there, the two write. “Excuse me,” she said, “it's the Northern Triangle – not immigration.”
Biden eventually clarified the mission. “It’s not her full responsibility,” he later told reporters, but “when she speaks, she speaks for me.”
Whether she wanted the job or not, Harris embraced the challenge. She has made three trips to the region, and she traveled to the southern border to hear directly from Border Patrol. The vice president has met both with law enforcement and migrant groups, stressing all the while that the question “cannot be reduced to a political issue.”
Politics were there from the beginning though, and some feared that deputizing Harris to tackle such a mammoth challenge ran the risk of unfairly saddling her with a thankless mission for which there is no easy solution. “She is qualified to do the job,” Chuck Rocha told RCP of Biden’s decision to turn this part of his policy portfolio over to his vice president. Rocha helmed Latino outreach for Sen. Bernie Sanders in both of that candidate’s presidential bids, and Rocha credited Harris for being “a staunch advocate of the progressive wing of the immigration movement.”
All the same, Rocha warned last year that expectations should be tempered: “It has been an issue that we have been trying to fix for generations, one that I don’t think any one person can totally solve.”
Biden has called on Congress to take up comprehensive immigration reform since he got to the White House. There is no bipartisan appetite on Capitol Hill for the bill that he sent to Congress on his first day in office. The administration has subsequently been left to its own devices, and Harris released a 20-page plan last July to address the problem.
“We will build on what works, and we will pivot away from what does not work,” Harris wrote in an introduction to the plan that focuses on creating partnerships with Northern Triangle countries to combat corruption, violence, and poverty.
“It will not be easy, and progress will not be instantaneous,” the vice president warned, “but we are committed to getting it right.” Biden should know. He was deputized by then-President Obama to deal with a similar mission amid an earlier surge of migrants, many of them unaccompanied children. On a tour of Central and South American nations in 2014, he offered U.S. help to root out corruption, provide economic opportunity, and ensure safety in the Northern Triangle nations.
“We have to deal with the root causes,” Vice President Biden told reporters gathered for a press conference in the residence of the U.S. ambassador to Guatemala, echoing the exact phrase his administration now uses eight years later.
Biden understands the challenge, and that tackling it without help from Congress is arduous and thankless, if not impossible.
“I said when we became a team and got elected, that the vice president was going to be the last person in the room,” he joked last March when he announced that Harris would helm the mission. “She didn’t realize that means she gets every assignment.”
“I gave you a tough job, and you’re smiling, but there’s no one better capable of trying to organize this for us,” the president continued after the levity. The vice president didn’t flinch. She thanked him “for having confidence in me.” Then Harris added, “there’s no question that this is a challenging situation.”
Everything You Want To Know About Monkeypox, But Were Afraid To Ask
DOJ Announces Hate Crimes And ‘Bias-Related’ Initiatives Including Reporting Hotline
National Poll: Safety not always top of mind for parents choosing kids’ summer camps
Bullwhip Effect Ends With A Bang: Why Prices Are About To Fall Off A Cliff
Bloated Inventories Hit Walmart, Target And Other Retailers’ Profits, Trucking Demand
Georgia’s Record-Breaking Early Voting Turnout Defies “Voter Suppression” Accusations
Why We Must Resist Geoeconomic Fragmentation—And How
The Monkeypox Virus: What You Need To Know
How This Ends
Top Stock Market News For Today May 23, 2022
Economics4 hours ago
U.S. Experienced Highest Ever Combined Rates of Deaths Due to Alcohol, Drugs, and Suicide During the COVID-19 Pandemic
Economics19 hours ago
QBE North America Provides Tips to Help Businesses Prepare for Hurricane Season
Economics24 hours ago
Top Stock Market News For Today May 23, 2022
Economics8 hours ago
Municipal Water and Wastewater Treatment Equipment Market Size to Increase by USD 16.02 Billion from 2021 to 2026| Technavio
International9 hours ago
Formula Shortage Highlights Supply Chain Concerns Facing Pharma Industry
International14 hours ago
Dr. Roger Härtl named AANS Humanitarian of the Year
Government11 hours ago
CDC Now Recommends COVID Testing For All Domestic Air Travel, Including The Vaccinated
Stocks14 hours ago
Tesla is down 33% in a month as analysts read more troubles. Where next?